Comprehensive Clinical Nursing & Pathophysiology Review

Cardiovascular Anatomy, Physiology, and Hemodynamics

  • Circulatory Flow Pathway:

    • Deoxygenated systemic venous return enters the right atrium via the superior and inferior venae cavae.
    • Blood traverses the tricuspid valve into the right ventricle.
    • The right ventricle expels blood across the pulmonary semilunar valve into the pulmonary artery toward the pulmonary capillary beds for gas exchange.
    • Oxygenated pulmonary venous blood returns via four pulmonary veins into the left atrium.
    • Blood passes across the mitral (bicuspid) valve into the left ventricle.
    • Contraction of the left ventricle ejects blood through the aortic valve into the ascending aorta to supply the systemic circulation.
    • The cardiac septum provides anatomical separation between the right and left pumps; structural wall defects are classified as atrial septal defects (ASD) or ventricular septal defects (VSD).

  • Cardiac Wall Structure and Properties:

    • The myocardium is the thick, contracting middle muscular layer of the heart wall.
    • The heart is encased externally in the pericardium, a protective double-layered fibroserous membrane.
    • Myocardial cells possess three fundamental physiological properties: contraction, autorhythmicity, and conduction.

  • Electrophysiology and Electrocardiography (ECG):

    • Action potentials initiate depolarization within myocardial tissue, triggering mechanical systole.
    • Impulses originate intrinsically within the sinoatrial (SA) node, the physiological pacemaker located in the superior right atrium.
    • The atrioventricular (AV) node delays impulse transmission between atria and ventricles, allowing complete atrial emptying before ventricular excitation.
    • Purkinje fibres rapidly propagate electrical impulses across ventricular myocardial tissue to stimulate synchronized ventricular contraction.
    • The standard ECG deflection waves correspond to specific electrophysiological events:
      • P wave: Represents atrial depolarization.
      • QRS complex: Represents ventricular depolarization (conduction through the AV node, bundle branches, and Purkinje network).
      • T wave: Represents ventricular repolarization.
      • ST segment: Serves as a sensitive indicator of myocardial ischemia (ST depression below the isoelectric line) or acute injury/infarction (ST elevation above the isoelectric line).

  • Mechanical Cardiac Cycle:

    • Systole denotes active myocardial contraction and ventricular ejection.
    • Diastole denotes myocardial relaxation and ventricular filling.
    • Rapid Filling Phase: Occurs in early diastole when ventricular myocardium relaxes, causing intraventricular pressure to fall below atrial pressure; atrioventricular valves (mitral and tricuspid) open passively, enabling rapid ventricular inflow.
    • Second Heart Sound ("dub"): Produced by the simultaneous closure of the aortic and pulmonary semilunar valves at the onset of diastole to prevent retrograde regurgitation into the relaxing ventricles.
    • Murmurs: Abnormal acoustic heart sounds generated by turbulent blood flow across stenotic, incompetent, or malformed valves and septal apertures.

  • Hemodynamic Calculations and Principles:

    • Cardiac Output (CO\text{CO}): Defined as the total volume of blood ejected by the heart per minute:         CO=Heart Rate (HR)×Stroke Volume (SV)\text{CO} = \text{Heart Rate (HR)} \times \text{Stroke Volume (SV)}
      • Example calculation: Given a stroke volume of 60 mL60\,\text{mL} and a heart rate of 90 beats/minute90\,\text{beats/minute}, the resulting cardiac output is:             CO=60 mL×90 beats/minute=5400 mL/minute=5.4 L/minute\text{CO} = 60\,\text{mL} \times 90\,\text{beats/minute} = 5400\,\text{mL/minute} = 5.4\,\text{L/minute}
    • Stroke Volume (SV\text{SV}): The absolute volume of blood expelled from a ventricle during a single contraction.
    • Ejection Fraction (EF\text{EF}): The proportion of end-diastolic ventricular volume expelled per systole, normally between 55–70%55\text{--}70\% (or 60–70%60\text{--}70\%).
    • Preload: The mechanical stretch placed on ventricular myocardial fibers at the completion of diastole, determined clinically by ventricular end-diastolic volume (EDV).
    • Afterload: The systemic vascular resistance or impedance the left ventricle must generate enough wall tension to overcome in order to eject blood into the systemic circulation.
    • Frank-Starling Law of the Heart: Demonstrates a proportional relationship between preload (end-diastolic volume) and stroke volume; greater diastolic myocardial stretch optimizes actin-myosin overlap, producing a stronger force of contraction during subsequent systole.
    • Inotropic Mechanism: Any physiological or pharmacological mechanism that amplifies myocardial contractility exerts a positive inotropic effect.
    • Colloid Osmotic Pressure: Generated within intravascular plasma predominantly by high concentrations of albumin, balancing capillary hydrostatic pressures.
    • Peripheral Vascular Resistance: The hydraulic ratio between systemic perfusion pressure gradients and volumetric blood flow rates.

  • Neural and Chemoreceptive Regulation:

    • Sympathetic Nervous System: Accelerates heart rate (tachycardia) and augments contractile force.
    • Parasympathetic Nervous System: Decelerates heart rate via the vagus nerve and promotes peripheral vasodilation; stimulates bronchial smooth muscle to cause bronchoconstriction.
    • Bradycardia: Defined in adults as a resting heart rate falling below 60 beats/minute60\,\text{beats/minute}.
    • Baroreceptors: Stretch-sensitive mechanoreceptors embedded within the carotid sinuses and the aortic arch that detect changes in systemic arterial blood pressure.
    • Central Chemoreceptors: Medullary sensors sensitive primarily to alterations in arterial carbon dioxide (PaCO2\text{PaCO}_2) and hydrogen ion concentration (pH\text{pH}).
    • Peripheral Chemoreceptors: Carotid and aortic bodies monitoring arterial fluctuations in pH\text{pH}, PaCO2\text{PaCO}_2, and oxygen tension (PaO2\text{PaO}_2).

Hypertension: Pathophysiology, Classification, and Pharmacotherapy

  • Blood Pressure Governing Formulas:

    • Blood Pressure (BP)=Cardiac Output (CO)×Systemic Vascular Resistance (SVR)\text{Blood Pressure (BP)} = \text{Cardiac Output (CO)} \times \text{Systemic Vascular Resistance (SVR)}
    • Arterial BP=Peripheral Resistance×Cardiac Output\text{Arterial BP} = \text{Peripheral Resistance} \times \text{Cardiac Output}
    • Cardiac output represents the primary hemodynamic determinant of systolic blood pressure.

  • Physiological Reflexes and Neurohormonal Compensations:

    • Baroreceptor Reflex: Acute arterial hypotension triggers immediate baroreceptor unloading, producing reflex sympathetic discharge that causes peripheral vasoconstriction and sinus tachycardia.
    • Renin-Angiotensin-Aldosterone System (RAAS): Activated in response to decreased renal perfusion, renal sympathetic nerve activity, or hyponatremia; beta-adrenergic inhibitors suppress renin release.
    • Angiotensin II Functions: Directly elevates systemic blood pressure by causing potent arteriolar vasoconstriction and by stimulating the adrenal cortex to secrete aldosterone.
    • Aldosterone Functions: Promotes active sodium and secondary water reabsorption within renal distal tubules and collecting ducts while enhancing potassium and hydrogen ion excretion, expanding intravascular volume.
    • Renal Pressure Diuresis: Normal kidneys counter elevations in systemic arterial blood pressure by increasing renal excretion of sodium and free water.
    • Atrial Natriuretic Peptide (ANP): Synthesized and released by atrial myocytes following wall stretch from elevated intravascular blood volume and blood pressure; promotes natriuresis, diuresis, and systemic vasodilation.

  • Classification and Risk Stratification:

    • Primary (Essential) Hypertension: Characterized by chronic elevations in systemic blood pressure lacking an identifiable secondary etiology; constitutes the vast majority of hypertensive presentations.
    • Isolated Systolic Hypertension: Diagnosed when systolic blood pressure exceeds 140 mmHg140\,\text{mmHg} with a concurrent diastolic blood pressure below 90 mmHg90\,\text{mmHg}.
    • Mild Hypertension: Defined by blood pressure parameters such as 149/94 mmHg149/94\,\text{mmHg}.
    • Moderate Hypertension: Defined by blood pressure parameters such as 165/100 mmHg165/100\,\text{mmHg}.
    • Non-Modifiable Risk Factors: Advancing chronological age, genetic predisposition, and positive family history.
    • Modifiable Risk Factors: High dietary sodium intake, obesity, physical inactivity, cigarette smoking, excess alcohol (ETOH) consumption, and unmanaged psychosocial stress.
    • Pathophysiological Mechanisms: Sustained sympathetic nervous system hyperactivity, chronic RAAS hyperstimulation, endothelial dysfunction, and vascular remodeling.

  • Target-Organ Sequelae:

    • Endothelial Injury: Shear stress damages large- and medium-sized arterial intimal layers, accelerating atheroma development.
    • Cerebrovascular Disease: Significantly increases the relative risk for ischemic stroke and intracerebral hemorrhage.
    • Ocular Disease: Induces microvascular hypertensive retinopathy.
    • Renal Disease: Glomerulosclerosis leading to chronic kidney disease.

  • Non-Pharmacological and Pharmacological Interventions:

    • Lifestyle Modifications: Regular aerobic cardiovascular exercise, sodium restriction, weight normalization, and avoidance of tobacco and excessive alcohol.
    • Angiotensin-Converting Enzyme (ACE) Inhibitors:
      • Agents: Captopril, Enalapril.
      • Mechanism of Action: Inhibit the ACE enzyme, blocking the systemic conversion of angiotensin I into the active vasoconstrictor angiotensin II; reduces peripheral vascular resistance (afterload) and decreases aldosterone secretion.
      • Therapeutic Goal: Reduction of systemic blood pressure and mitigation of ventricular remodeling.
      • Adverse Reactions: Persistent dry non-productive cough mediated by the accumulation of inflammatory bradykinins and substance P; life-threatening angioedema manifesting as rapid submucosal and airway swelling.
    • Angiotensin II Receptor Blockers (ARBs):
      • Agents: Candesartan, Irbesartan.
      • Mechanism of Action: Competitively bind and block type-1 angiotensin II (AT1\text{AT}_1) receptors on arteriolar vascular smooth muscle and the adrenal cortex, blunting vasoconstriction and aldosterone release without altering bradykinin breakdown.
    • Calcium Channel Blockers (CCBs):
      • Agents: Amlodipine, Felodipine, Nifedipine.
      • Mechanism of Action: Inhibit L-type voltage-gated calcium channels within peripheral vascular smooth muscle, suppressing calcium influx and inducing sustained arteriolar vasodilation.
    • Beta-Adrenergic Antagonists (Beta-Blockers):
      • Selective β1\beta_1-Adrenoceptor Antagonists: Atenolol, Metoprolol, Bisoprolol. Exert targeted negative inotropic and chronotropic effects on cardiac tissue, lowering cardiac output and suppressing renin release.
      • Non-Selective β1\beta_1 and β2\beta_2-Adrenoceptor Antagonists: Propranolol, Timolol.
    • Diuretics:
      • Thiazide Diuretics: Hydrochlorothiazide, Bendroflumethiazide. Inhibit sodium-chloride cotransporters in distal convoluted tubules.
      • Loop Diuretics: Furosemide (Lasix). Blocks the Na+−K+−2Cl−\text{Na}^+-\text{K}^+-2\text{Cl}^- cotransporter in the thick ascending limb of the loop of Henle to inhibit sodium and water reabsorption, reducing effective circulating blood volume.

Atherosclerosis and Acute Coronary Syndromes (ACS)

  • Pathogenesis of Atherosclerosis:

    • Initial Insult: Chronic shear stress, hypertension, or free-radical exposure damages arterial intimal endothelium.
    • Lipid Transport and Retention: Low-Density Lipoprotein (LDL, the principal systemic carrier of cholesterol) penetrates the compromised intima and undergoes oxidative modification into oxidized LDL.
    • Fatty Streak Formation: Circulating monocytes migrate into the subendothelial space, differentiate into macrophages, and phagocytose oxidized LDL via scavenger receptors, transforming into lipid-laden foam cells. Fatty streaks represent the earliest visible gross anatomical lesion of atherogenesis.
    • Plaque Maturation: Smooth muscle proliferation, extracellular matrix deposition, and collagen synthesis create an atherosclerotic fibrocalcific plaque with a central necrotic core.
    • Dietary Effects: High dietary saturated fat intake downregulates cellular clearance of circulating LDLs.

  • Acute Coronary Syndrome Spectrum:

    • Includes Unstable Angina (UA), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), and ST-Segment Elevation Myocardial Infarction (STEMI).
    • Primary Pathophysiological Trigger: Rupture, erosion, or fissure of an unstable atherosclerotic fibrous plaque, exposing subendothelial collagen to circulating blood.
    • Thrombus Genesis: Platelet adhesion, activation, and aggregation form an intracoronary thrombus via intrinsic and extrinsic coagulation cascades, producing transient or permanent vessel occlusion.
    • Ischemic Cascade: Tissue necrosis begins in the vulnerable subendocardium within minutes of severe coronary flow restriction and progresses outward toward the epicardium.

  • Coronary Arterial Anatomy and Localization:

    • Left Anterior Descending (LAD) Artery: Perfuses the anterior myocardial wall of the left ventricle and anterior interventricular septum.
    • Right Coronary Artery (RCA): Supplies the inferior myocardial wall, right ventricle, and conduction nodes; occlusions manifest electrographically in inferior leads II, III, and aVF.

  • Diagnostic Markers and Electrocardiography:

    • Cardiac Troponin (Troponin T and Troponin I): The gold-standard diagnostic biomarker for acute myocardial necrosis due to absolute cardiac-tissue specificity; STEMI diagnosis involves ST elevation with cardiac troponin elevations exceeding 14 ng/L14\,\text{ng/L}.
    • Electrocardiographic Waves: STEMI presents with pathological ST-segment elevation above the isoelectric baseline; acute ischemia manifests as ST-segment depression or T-wave inversion; loss of P waves is not a characteristic sign of myocardial infarction.

  • Clinical Presentation:

    • Classic Features: Severe, substernal "crushing" chest pressure or tightness lasting longer than 20 minutes20\,\text{minutes}, radiating into the jaw, neck, epigastrium, or left arm.
    • Associated Symptoms: Profuse diaphoresis, exertional dyspnea, nausea, vomiting, dizziness, and intense anxiety.
    • Atypical Symptoms: Sharp, stabbing pain that worsens on deep inspiration is characteristic of pleuritis or pericarditis rather than classic ischemic ACS.

  • Complications of Myocardial Infarction:

    • Arrhythmias/Dysrhythmias: The most frequent early, life-threatening complication of acute myocardial infarction.
    • Acute Cardiogenic Heart Failure: Extensive anterior wall infarctions compromise left ventricular systolic performance, causing backward failure and cardiogenic pulmonary edema.
    • Histological Remodeling: Non-viable necrotic cardiomyocytes are progressively phagocytosed and replaced by non-contractile fibrous collagen scar tissue.

  • Emergency Therapeutic Management:

    • Reperfusion Principle: "Time is Muscle" emphasizes that delays in restoring coronary artery patency increase irreversible cardiomyocyte necrosis.
    • Primary Percutaneous Coronary Intervention (PCI): The gold-standard mechanical reperfusion method, utilizing balloon angioplasty and stenting to dilate blocked coronary vessels.
    • Aspirin (Acetylsalicylic Acid): Administered immediately at suspicion (e.g., 300 mg300\,\text{mg} loading dose); irreversibly acetylates cyclooxygenase-1, inhibiting thromboxane A2\text{A}_2 synthesis and preventing platelet aggregation.
    • Nitroglycerin / Glyceryl Trinitrate (GTN): Induces peripheral venodilation (decreasing preload) and coronary arteriolar dilation (reducing afterload), lowering myocardial oxygen demand while relieving coronary vasospasm.
    • Morphine: Acts centrally to relieve intractable chest pain and sympathetic anxiety, lowering myocardial metabolic demand.
    • Oxygen Administration: Indicated selectively when pulse oximetry falls below 94%94\%.
    • Thrombolytic / Fibrinolytic Pharmacotherapy:
      • Agents: Recombinant tissue plasminogen activators (tPA) such as Alteplase (Cathflo Activase) and Tenecteplase.
      • Mechanism: Converts endogenous plasminogen into plasmin, an active enzyme that digests fibrin meshworks within coronary thrombi to re-establish blood flow.
      • Complications: Major risk of fatal cerebral hemorrhage; strictly contraindicated in the setting of prior hemorrhagic stroke.
      • Antidote: Aminocaproic acid serves as an antifibrinolytic reversal agent.

Heart Failure and Cardiogenic Complications

  • Definition and Mechanical Classifications:

    • Heart Failure: A complex clinical syndrome secondary to structural or functional cardiac abnormalities that impair the ability of the ventricles to fill with blood (diastolic dysfunction) or eject blood (systolic dysfunction).
    • Systolic Heart Failure (Heart Failure with reduced Ejection Fraction, HFrEF): Characterized by a marked mechanical reduction in myocardial force generation during systole, lowering ejection fraction.

  • Neurohormonal Maladaptations and Remodeling:

    • Decline in cardiac output triggers persistent activation of the sympathetic nervous system and the RAAS.
    • Chronic neurohormonal hyperactivation increases afterload, promotes circulating volume retention, heightens myocardial oxygen requirements, drives ventricular remodeling, and accelerates cardiac decompensation.
    • B-Type Natriuretic Peptide (BNP): An endocrine hormone released by ventricular myocardium in response to increased intracardiac wall tension and volume overload; serves as a diagnostic and prognostic biomarker for heart failure.

  • Left-Sided versus Right-Sided Heart Failure:

    • Left-Sided Heart Failure: Inability of the left ventricle to pump blood forward into the systemic circulation; blood pools upstream into the left atrium and pulmonary venous circulation.
      • Clinical Manifestations: Tachypnea, exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough, peripheral cyanosis, and bilateral basal crackles/crepitations on chest auscultation.
      • Cardiogenic Pulmonary Edema: Left ventricular decompensation causes extreme elevations in pulmonary capillary hydrostatic pressure, exceeding plasma oncotic thresholds and driving transudative fluid into alveolar airspaces; presents with worsening breathlessness, anxiety, and expectoration of pink, frothy sputum.
    • Right-Sided Heart Failure: Most commonly caused by chronic left-sided heart failure due to transmission of elevated pulmonary pressures increasing right ventricular afterload; manifests with systemic venous congestion, dependent peripheral ankle edema, hepatomegaly, and elevated jugular venous pressure.

  • Diagnostic Modalities and Long-Term Pharmacotherapy:

    • Transthoracic Echocardiogram (TTE): Ultrasound imaging used to non-invasively evaluate internal cardiac structures, assess ventricular wall motion, and calculate ejection fraction.
    • ACE Inhibitors (e.g., Captopril): Long-term treatment designed to reduce peripheral vascular resistance (afterload), decrease aldosterone-mediated sodium retention, and blunt progressive ventricular remodeling.
    • Beta-Blockers (e.g., Bisoprolol): Inhibit toxic sympathetic overstimulation, decelerate heart rate, lower myocardial oxygen consumption, and improve long-term clinical survival.
    • Cardiac Glycosides (Digoxin / Lanoxin): Inhibits the myocardial cell membrane Na+/K+\text{Na}^+/\text{K}^+-ATPase pump, resulting in intracellular calcium accumulation that produces a positive inotropic increase in contractile force.

Respiratory Physiology, Mechanics, and Blood Gas Dynamics

  • Gas Exchange and Transport Processes:

    • Oxygen Delivery Sequence: (1) Pulmonary ventilation (inflow of ambient air into alveoli); (2) Diffusion of alveolar oxygen across the alveolar-capillary barrier into blood; (3) Perfusion of systemic capillaries with oxygen-enriched arterial blood; (4) Passive diffusion of dissolved oxygen from systemic capillaries into peripheral tissue cells.
    • Carbon Dioxide Removal: Follows the exact reverse mechanical and diffusive order of oxygen delivery.
    • Alveolar-Capillary Diffusion Interface: Features an ultra-thin cellular membrane (less than 0.5 μm0.5\,\mu\text{m}) paired with a massive total alveolar surface area, maximizing gas diffusion rates.

  • Respiratory Mechanics and Lung Volumes:

    • Inspiratory Musculature: At rest, quiet inspiration is driven primarily by contraction of the diaphragm, aided by external intercostal muscles. The diaphragm is a dome-shaped musculotendinous septum separating the thoracic and abdominal/pelvic cavities.
    • Mechanism of Inflow: Diaphragmatic contraction causes it to flatten downward, expanding vertical and cross-sectional thoracic cavity dimensions; this generates negative intrathoracic subatmospheric pressure that draws ambient air inward.
    • Tidal Volume (VT\text{V}_T): The volume of air inspired or expired during a normal, unforced resting respiratory cycle.
    • Alveolar Ventilation: The specific volumetric fraction of inspired ventilation that reaches the respiratory bronchioles and alveoli to directly take part in active gas exchange.
    • Forced Vital Capacity (FVC): The total volume of air exhaled forcefully and rapidly following maximal inhalation.
    • Forced Expiratory Volume (FEV1\text{FEV}_1): Healthy individuals forcefully exhale 80–85%80\text{--}85\% of their vital capacity within the first second of expiration (FEV1/FVC≥0.80\text{FEV}_1/\text{FVC} \ge 0.80).
    • Airway Resistance: Inversely related to the fourth power of the internal airway radius; determined predominantly by the anatomical diameter of intermediate and small airways.
    • Conducting Zone Hierarchy: Atmospheric air traverses the trachea, mainstem bronchi, lobar bronchi, segmentary bronchi, and terminal bronchioles before reaching gas-exchanging units (respiratory bronchioles and alveoli); no gas exchange occurs within the conducting anatomical dead space.

  • Ventilation-Perfusion (V/Q\text{V/Q}) Relationships:

    • Low V/Q\text{V/Q} Ratio: Signifies lung regions where alveolar ventilation is deficient relative to vascular perfusion, producing physiological shunting.
    • Capillary Shunt: Defined as unoxygenated blood passing pulmonary capillaries adjacent to entirely unventilated alveoli, returning unoxygenated to the left heart.

  • Physiological Control of Respiration:

    • Ventilation is regulated by three integrated systems: neural centers (medullary rhythmicity generators), mechanical inputs (pulmonary stretch receptors), and chemical sensors.
    • Arterial carbon dioxide tension (PaCO2\text{PaCO}_2) represents the most sensitive biological indicator of alveolar ventilation adequacy.

  • Arterial Blood Gas (ABG) Interpretations and Classifications:

    • Hypoxemia: Defined as an abnormally low partial pressure or concentration of oxygen dissolved in arterial blood (PaO2\text{PaO}_2).
    • Type I Respiratory Failure: Hypoxemic failure characterized by an arterial oxygen tension PaO2<60 mmHg\text{PaO}_2 < 60\,\text{mmHg} with normal or low arterial carbon dioxide tension.
    • Type II Respiratory Failure: Hypercapnic ventilatory failure characterized by an arterial carbon dioxide tension PaCO2>50 mmHg\text{PaCO}_2 > 50\,\text{mmHg}, often coexisting with hypoxemia.
    • ABG Example 1: pH 7.30\text{pH } 7.30, PaCO2=55 mmHg\text{PaCO}_2 = 55\,\text{mmHg}, PaO2=50 mmHg\text{PaO}_2 = 50\,\text{mmHg}, HCO3−=28 mmol/L\text{HCO}_3^- = 28\,\text{mmol/L} reflects Acute Respiratory Acidosis with Hypoxemia.
    • ABG Example 2: pH 7.32\text{pH } 7.32, PaCO2=58 mmHg\text{PaCO}_2 = 58\,\text{mmHg}, PaO2=54 mmHg\text{PaO}_2 = 54\,\text{mmHg}, HCO3−=26 mmol/L\text{HCO}_3^- = 26\,\text{mmol/L}, SaO2=84%\text{SaO}_2 = 84\%, Base Excess (BE)=−4\text{Base Excess (BE)} = -4 reflects Respiratory Acidosis with Hypoxemia.
    • ABG Example 3: pH 7.38\text{pH } 7.38, PaCO2=42 mmHg\text{PaCO}_2 = 42\,\text{mmHg}, PaO2=59–60 mmHg\text{PaO}_2 = 59\text{--}60\,\text{mmHg} reflects isolated Hypoxemia with preserved systemic acid-base equilibrium.
    • ABG Example 4: pH 7.52\text{pH } 7.52, PaCO2=30 mmHg\text{PaCO}_2 = 30\,\text{mmHg}, PaO2=60 mmHg\text{PaO}_2 = 60\,\text{mmHg}, HCO3−=28 mmol/L\text{HCO}_3^- = 28\,\text{mmol/L}, SaO2=96%\text{SaO}_2 = 96\% reflects Respiratory Alkalosis.
    • Compensated Respiratory Acidosis: Characterized by chronic elevations in PaCO2\text{PaCO}_2 (e.g., 55 mmHg55\,\text{mmHg}), high renal bicarbonate retention (HCO3−=28 mmol/L\text{HCO}_3^- = 28\,\text{mmol/L}), and a near-normal pH\text{pH} (e.g., 7.357.35).

Chronic Obstructive Pulmonary Disease (COPD) and Respiratory Failure

  • Etiology and Pathological Subtypes:

    • Primary Etiology: Chronic inhalation of tobacco smoke is the leading cause of COPD.
    • Chronic Bronchitis: Clinically defined by chronic airway inflammation, goblet cell hypertrophy, and persistent mucus hypersecretion with productive cough.
    • Emphysema: Defined anatomically by irreversible enzymatic destruction of alveolar walls and capillary beds, with abnormal, permanent airspace enlargement distal to terminal bronchioles.
    • Cellular Mediators: Involves recruitment of inflammatory neutrophils and alveolar macrophages; excessive release of cellular reactive oxygen species (oxidative stress) produces parenchymal injury; overactivity of endogenous neutrophil elastase degrades alveolar elastin fibers, destroying lung recoil.
    • Mechanics of Dyspnea: Loss of elastic recoil causes dynamic airway collapse during expiration, producing gas trapping and pulmonary hyperinflation; hyperinflation displaces and flattens the diaphragm downward, impairing its mechanical efficiency and increasing the work of breathing.

  • Differentiating COPD from Asthma:

    • Asthma: An allergic airway inflammatory disease linked to atopic allergy (genetic predisposition to eczema, allergic rhinitis, and asthma); features reversible bronchospasm and variable airflow limitation.
    • COPD: Exhibits largely irreversible and progressive airflow obstruction; while airflow limitation may improve marginally when acute exacerbations resolve, underlying architectural limitation persists.

  • Clinical Presentation and Exacerbation Dynamics:

    • Exacerbation Definition: An acute change in baseline respiratory parameters characterized by sudden worsening of dyspnea, increased cough frequency, and changes in sputum volume or purulence. Increased exercise tolerance or fluid retention are not features.
    • Triggers: Upper or lower respiratory tract infections (viral or bacterial) and exposure to particulate environmental pollutants.
    • Clinical Phenotypes: "Blue bloaters" describes patients with chronic bronchitis and advanced Type II hypercapnic respiratory failure, cyanosis, and systemic edema secondary to cor pulmonale.
    • Psychological Burden: High prevalence of severe secondary anxiety and depression due to chronic breathlessness.
    • Diagnostic Workup: Chest radiography is utilized to rule out alternative pathologies (such as pneumonia, pneumothorax, or bronchogenic carcinoma); sputum microbiology guides targeted antibiotic administration; arterial blood gas analysis is indicated when SpO2<92%\text{SpO}_2 < 92\% or when breathlessness is out of proportion to clinical signs.

  • Management Protocols and Oxygen Delivery:

    • Smoking Cessation: The most critical, disease-modifying intervention known to arrest the progressive decline of FEV1\text{FEV}_1.
    • Controlled Oxygen Therapy: Target oxygen saturation in acute COPD exacerbations is strictly 88–92%88\text{--}92\%.
    • Hazards of Hyperoxia ("Hypoxic Drive"): In chronic hypercapnia, central chemoreceptors downregulate sensitivity to high PaCO2\text{PaCO}_2, leaving peripheral chemoreceptors dependent on low arterial oxygen levels (PaO2\text{PaO}_2) to stimulate respiration. High-flow oxygen administration abolishes this hypoxic ventilatory drive, inducing hypoventilation, severe hypercapnia, respiratory acidosis, and potential respiratory arrest (apnea).
    • Oxygen Masks: The minimum permissible operational oxygen flow delivered through a standard Hudson mask is 4 L/min4\,\text{L/min} to prevent carbon dioxide rebreathing within the mask reservoir.
    • Long-Term Oxygen Therapy (LTOT): Documented to improve long-term survival in patients with severe baseline hypoxemia.
    • Pursed-Lip Breathing: Creates positive expiratory back-pressure within conducting airways, splinting small bronchioles open to prevent dynamic expiratory collapse and reduce gas trapping.
    • Chest Physiotherapy: Does not prevent aspiration pneumonia.
    • Non-Invasive Ventilation (BiPAP): Indicated in acute exacerbations with hypercapnic respiratory acidosis; delivers positive inspiratory and expiratory pressures to augment alveolar ventilation and eliminate ("blow off") carbon dioxide.

  • Pharmacotherapy:

    • Short-Acting Bronchodilators: Inhaled short-acting β2\beta_2-agonists (SABA, e.g., Salbutamol / Ventolin) relax bronchial smooth muscle; short-acting anticholinergics (SAMA, e.g., Ipratropium bromide) block muscarinic receptors to prevent acetylcholine-mediated bronchoconstriction.
    • Long-Acting Bronchodilators: Administered regularly for continuous, long-term symptom maintenance.
    • Inhaled Corticosteroids (ICS): Administered to suppress chronic airway mucosal inflammation and decrease exacerbation frequency.
    • Systemic Antibiotics: Reserved for acute exacerbations triggered by purulent bacterial infections.

Ischaemic Stroke: Pathophysiology, Localization, and Acute Management

  • Etiology and Epidemiology:

    • Prevalence: Ischemic stroke accounts for approximately 85%85\% of all cerebrovascular accidents (CVAs).
    • Etiology: Caused by sudden arterial occlusion secondary to an embolus originating from the heart (e.g., atrial fibrillation) or carotid arteries, or in situ thrombotic occlusion over an unstable atherosclerotic plaque.
    • Pathophysiological Sequence: Atherosclerosis →\rightarrow thrombus formation at atherosclerotic site →\rightarrow arterial occlusion →\rightarrow focal ischemia →\rightarrow cerebral infarction.
    • Modifiable Risk Factors: Systemic hypertension, diabetes mellitus, cigarette smoking, atrial fibrillation, and oral contraceptive pill use. Hypertension and diabetes are strong risk factors for small-artery (lacunar) thrombotic stroke.

  • Cellular Ischemic Cascades and Cerebral Topography:

    • Zones of Injury:
      • Core Ischemic Zone: The central area of severe hypoperfusion where cellular death is immediate, complete, and irreversible.
      • Ischemic Penumbra: The surrounding border zone of hypoperfused, metabolically compromised but structurally viable tissue; restoring perfusion promptly preserves this penumbral tissue.
    • Cytotoxic Edema: Ischemia causes cellular energy (ATP) exhaustion, leading to failure of the ATP-dependent sodium-potassium pump (Na+/K+\text{Na}^+/\text{K}^+-ATPase). Intracellular accumulation of sodium and calcium ions draws free water in osmotically, producing cytotoxic cellular swelling.
    • Circle of Willis: Provides a vascular ring connecting anterior and posterior cerebral circulations, allowing collateral blood flow if an afferent vessel becomes occluded.
    • Pyramidal Decussation: Descending motor tracts cross over in the lower medulla oblongata; an ischemic infarct located within the left motor cortex or internal capsule manifests as contralateral (right-sided) motor hemiplegia.
    • Left Middle Cerebral Artery (MCA) Occlusion: Classically presents with right-sided hemiparesis (arm greater than leg), right-sided facial droop, and expressive dysphasia (inability to articulate or form words, associated with Broca's area in the left frontal lobe) or receptive dysphasia (Wernicke's area in the temporal lobe).

  • Diagnostic Assessment and Emergency Care:

    • F.A.S.T. Screening Tool: Face (drooping), Arms (weakness or drift), Speech (difficulty or slurring), Time (emergency medical response).
    • Emergency Neuroimaging: Non-contrast Computed Tomography (CT) brain scan is mandatory to rule out acute intracranial hemorrhage before starting thrombolytic therapy.
    • Intravenous Thrombolytic Therapy:
      • Agent: Recombinant tissue plasminogen activator (tPA, Alteplase).
      • Mechanism of Action: Converts plasminogen into plasmin, an active enzyme that digests the fibrin meshwork of intravascular thrombi.
      • Therapeutic Time Window: Must be administered within 4.5 hours4.5\,\text{hours} of verified symptom onset (extended to 6 hours6\,\text{hours} in select protocols).
      • Absolute Contraindication: Any radiographic evidence of intracranial hemorrhage on CT scan.
    • Endovascular Clot Retrieval (ECR): Mechanical catheter-based thrombectomy to extract large-vessel occlusive thrombi within proximal cerebral vessels.
    • Secondary Stroke Prevention: High-dose statin therapy; antiplatelet regimens like Asasantin (a combination of dipyridamole and aspirin targeting platelet activation).
    • Transient Ischemic Attack (TIA): A temporary episode of focal neurological dysfunction caused by vascular ischemia without acute parenchymal infarction.
    • Nursing Interventions: Airway stabilization; continuous neurological checks; monitoring for signs of elevated intracranial pressure.
    • Dysphagia Precautions: Stroke impairs the sensory and motor nerves controlling the pharynx; strict aspiration precautions dictate that oral fluids and solids must be held until swallowing ability is confirmed; soft foods such as scrambled eggs are appropriate for patients with mild dysphagia.

Haemorrhagic Stroke, Intracranial Dynamics, and Neuro-Critical Care

  • Etiology and Subtypes:

    • Intracerebral Hemorrhage (ICH): Bleeding directly into brain parenchyma, most commonly caused by chronic, untreated systemic hypertension.
    • Subarachnoid Hemorrhage (SAH): Extravasation of blood into the subarachnoid space between the arachnoid membrane and the pia mater (the compartment containing cerebrospinal fluid), commonly caused by rupture of a saccular (berry) aneurysm.
    • Clinical Signs: Severe, sudden-onset "thunderclap" headache, nausea, projectile vomiting, photophobia (sensitivity to light), altered sensorium, and signs of meningeal irritation.

  • Diagnostic Confirmation:

    • SAH is confirmed via clinical presentation, non-contrast CT brain scan, and lumbar puncture (evaluating cerebrospinal fluid for red blood cells and xanthochromia); verbal response scoring alone is non-diagnostic.

  • Intracranial Dynamics and the Monro-Kellie Doctrine:

    • Monro-Kellie Doctrine: States that the rigid, non-distensible cranial vault has a fixed total volume containing brain tissue, intravascular blood, and cerebrospinal fluid (CSF); an increase in the volume of one constituent must be offset by an equal reciprocal reduction in another, or intracranial pressure (ICP) will rise.
    • Cerebral Perfusion Pressure (CPP): The net pressure gradient driving cerebral blood flow, defined by the formula:         CPP=Mean Arterial Pressure (MAP)−Intracranial Pressure (ICP)\text{CPP} = \text{Mean Arterial Pressure (MAP)} - \text{Intracranial Pressure (ICP)}
    • Pupillary Reflexes: Herniation or raised supratentorial ICP compresses the third cranial nerve (Oculomotor nerve, CN III), paralyzing pupilloconstrictor fibers and producing an ipsilateral fixed, dilated pupil.

  • Neuro-Critical Care Management:

    • Primary Management Goal: Rapid reduction of intracranial pressure and prevention of herniation.
    • Patient Positioning: Elevate the head of the bed to 30∘30^\circ with the head in a neutral midline position to facilitate jugular venous outflow and lower ICP.
    • Osmotic Therapy: Intravenous Mannitol serves as an osmotic diuretic, increasing plasma osmolarity to draw water out of the cerebral parenchyma into the vascular space, reducing cerebral edema and ICP.
    • Anticoagulation Reversal:
      • Warfarin-induced coagulopathy presents with an elevated, prolonged International Normalized Ratio (INR).
      • Vitamin K is administered to stimulate hepatic synthesis of vitamin K-dependent clotting factors.
      • Fresh Frozen Plasma (FFP) provides immediate replacement of active clotting factors.
    • Heparin-Induced Thrombocytopenia (HIT): An immune-mediated reaction causing an abrupt drop in platelet count accompanied by paradoxical, life-threatening arterial and venous thrombosis.
    • Cerebral Vasospasm Prophylaxis: Oral Nimodipine, a lipophilic dihydropyridine calcium channel blocker, is administered in SAH to prevent cerebral arterial vasospasm and secondary ischemic deficits.
    • Surgical Contraindications: Craniotomy or clot evacuation is contraindicated in the presence of massive, destructive hematomas with irreversible brainstem failure.
    • Neurological Monitoring: Serial assessments using the Glasgow Coma Scale (GCS) and pupil reactivity are mandatory.

Renal Physiology, Acute Kidney Injury (AKI), and Chronic Kidney Disease (CKD)

  • Renal Anatomy, Filtration, and Endocrine Function:

    • Nephron: The microscopic structural and functional unit of the kidney; responsible for plasma filtration, tubular reabsorption, and tubular secretion; nephrons do not regulate systemic blood glucose levels.
    • Perfusion: The kidneys receive 20–25%20\text{--}25\% of resting cardiac output (they do not receive 80–90%80\text{--}90\%).
    • Processes of Urine Formation: (1) Glomerular filtration; (2) Tubular reabsorption; (3) Tubular secretion.
    • Proximal Convoluted Tubule (PCT): Reabsorbs 60–65%60\text{--}65\% of filtered water and virtually all filtered electrolytes, amino acids, and glucose back into peritubular capillaries.
    • Endocrine Functions: The kidneys secrete Erythropoietin (EPO) to stimulate bone marrow erythropoiesis, secrete Renin to regulate blood pressure, and hydroxylate inactive precursors into active Vitamin D (Calcitriol); the kidneys do not secrete Vitamin D itself.
    • Antidiuretic Hormone (ADH / Vasopressin): Regulates systemic fluid retention and urine concentration via aquaporin insertion, directly affecting arterial blood pressure.
    • Diagnostic Markers: Estimated Glomerular Filtration Rate (eGFR) provides the best overall index of functional kidney capacity; serum creatinine elevation indicates declining GFR; urine specific gravity (normal range 1.003–1.0301.003\text{--}1.030) measures renal concentrating capacity.

  • Acute Kidney Injury (AKI):

    • Pre-Renal AKI: Caused by transient renal hypoperfusion secondary to systemic hypotension, hypovolemia, or severe dehydration.
    • Intra-Renal AKI: Caused by intrinsic parenchymal damage, most commonly Acute Tubular Necrosis (ATN) from prolonged ischemia or nephrotoxic agents.
    • Post-Renal AKI: Arises from acute urinary tract obstruction (e.g., calculi, prostatic hypertrophy), causing retrograde hydrostatic back-pressure and parenchymal ischemia.
    • Initiation Phase: The time interval between the initial nephrotoxic or ischemic insult and the onset of reduced renal excretory function.
    • Clinical Signs: Oliguria (early sign) and anuria, defined as urine output falling below 100 mL/day100\,\text{mL/day}.
    • Resuscitation Fluids: Hartmann's solution is a balanced crystalloid solution containing physiological concentrations of electrolytes and lactate.

  • Chronic Kidney Disease (CKD) Pathophysiology and Staging:

    • Etiology: The leading causes of CKD are long-standing Diabetes Mellitus and systemic Hypertension.
    • Staging by Glomerular Filtration Rate:
      • Stage 1: Normal or elevated eGFR (≥90 mL/min\ge 90\,\text{mL/min}) accompanied by persistent structural kidney damage; eGFR may appear normal secondary to compensatory hyperfiltration.
      • Stage 4: Severe reduction in function, defined by an eGFR=15–29 mL/min\text{eGFR} = 15\text{--}29\,\text{mL/min}.
      • Stage 5 / End-Stage Renal Disease (ESRD): Defined by an eGFR<15 mL/min\text{eGFR} < 15\,\text{mL/min}, requiring renal replacement therapy.
    • "Trade-Off Hypothesis": As nephrons are progressively destroyed, surviving nephrons undergo compensatory hyperfiltration and hypertrophy; this long-term maladaptive hemodynamic workload induces glomerulosclerosis and accelerates nephron loss.
    • Autoregulation and Vulnerability: CKD kidneys lose their ability to autoregulate local blood flow to buffer fluctuations in systemic pressure; reduced renal reserve significantly increases susceptibility to superimposed acute-on-chronic kidney injury; intra-renal hypoxia drives progressive fibrotic damage.

  • Uremic Complications and Clinical Manifestations:

    • Four Life-Threatening Issues in Acute-on-Chronic Kidney Disease: Fluid Overload, Severe Metabolic Acidosis, Decreased Level of Consciousness (LOC), and Severe Hyperkalemia.
    • Hyperkalemia: Inability to excrete potassium; normal serum potassium reference range is 3.5–5.2 mmol/L3.5\text{--}5.2\,\text{mmol/L}; serum levels reaching 6.5 mmol/L6.5\,\text{mmol/L} risk fatal cardiac arrhythmias, treated with gastrointestinal potassium-binding resins (e.g., Resonium) or urgent dialysis.
    • Metabolic Acidosis: Develops from the inability of failing nephrons to excrete metabolic hydrogen ions (H+\text{H}^+) and synthesize ammonium, coupled with loss of filtered bicarbonate.
    • Anemia: Destruction of peritubular interstitial cells causes erythropoietin deficiency, resulting in normochromic, normocytic anemia.
    • Mineral and Bone Disorder (Renal Osteodystrophy): Hyperphosphatemia occurs due to decreased phosphate clearance; reciprocal hypocalcemia develops due to calcium-phosphate binding and deficient renal synthesis of active Vitamin D (Calcitriol); hypocalcemia and hyperphosphatemia stimulate parathyroid hyperplasia, producing Secondary Hyperparathyroidism; oral Calcitriol is administered to prevent and manage renal osteodystrophy.
    • Fluid Overload: Manifests as dependent ankle edema and hypertension; severe fluid retention causes pulmonary edema and congestive heart failure; managed via fluid restrictions and daily weight monitoring.
    • Uremic Syndrome: Systemic accumulation of nitrogenous waste produces lethargy, hyperreflexia, pericardial friction rub, and uremic encephalopathy with seizures and coma.

  • Renal Replacement Therapy and Dietary Modifications:

    • Dietary Restrictions: Diets for advanced CKD restrict protein (limiting nitrogenous waste), potassium, phosphate, and sodium.
    • Hemodialysis: Typically conducted 3 times/week3\,\text{times/week}; rapid fluid shifts commonly produce intradialytic hypotension; preferred for severe metabolic derangements.
    • Peritoneal Dialysis: Utilizes the peritoneum as a semipermeable membrane; the most frequent infectious complication is bacterial peritonitis.

Acute Lymphoblastic Leukaemia (ALL) and Hematologic Oncology

  • Hematopoiesis and Cellular Lineages:

    • Hematopoiesis: The physiological process of blood cell formation from pluripotent stem cells within bone marrow.
    • Lineage Differentiation: Pluripotent stem cells split into lymphoid and myeloid lines. The myelocyte lineage gives rise to basophils, eosinophils, and neutrophils; neutrophils are the most abundant circulating granulocyte.
    • Megakaryocytes: Large bone marrow precursor cells that fragment to produce thrombocytes (platelets).
    • Erythropoiesis: Regulated by the renal glycoprotein hormone erythropoietin.
    • Leukocytosis: An abnormal elevation in circulating, mature functional white blood cells.

  • Pathophysiology of Leukaemia:

    • Underlying Defect: Malignant transformation and uncontrolled proliferation of immature, non-functional white blood cell precursors (blasts).
    • Classification: Categorized by dominant cellular lineage (lymphoid vs. myeloid) and cellular maturity (acute vs. chronic).
    • Marrow Infiltration: Rapid blast accumulation crowdedly infiltrates and suppresses normal bone marrow architecture, causing pancytopenia (anemia, neutropenia, and thrombocytopenia).
    • Extramedullary Infiltration: Malignant blast cells cross the blood-brain barrier into the central nervous system and infiltrate the spleen, liver, and lymph nodes.

  • Epidemiology and Clinical Manifestations of ALL:

    • Peak Age: Most commonly diagnosed in children aged 3–10 years3\text{--}10\,\text{years}.
    • Clinical Triad from Marrow Failure:
      • Thrombocytopenia: Low platelet counts cause cutaneous petechiae, ecchymoses, and mucous membrane bleeding.
      • Neutropenia: Loss of functional granulocytes causes recurrent fevers and susceptibility to opportunistic infections; absolute neutrophil counts below 0.4×109 L−10.4 \times 10^9\,\text{L}^{-1} denote severe risk for life-threatening sepsis.
      • Anemia: Suppression of erythropoiesis leads to pallor, lethargy, and profound fatigue due to reduced oxygen-carrying capacity.
    • Extramedullary Features: Bone pain resulting from leukemic marrow expansion; bruising; fatigue; thrombophilia is not a feature.

  • Diagnostic Evaluation:

    • Bone Marrow Aspirate and Biopsy: The definitive diagnostic test to quantify blast percentage and establish immunophenotype.
    • Lumbar Puncture: Diagnostic procedure performed to sample cerebrospinal fluid (CSF) to confirm or rule out leukemic CNS involvement.

  • Chemotherapy Protocols and Chemotherapeutic Agents:

    • Three Core Treatment Phases:
      1. Induction Phase: Aggressive initial chemotherapy to eradicate visible leukemic burden and induce clinical remission (elimination of all detectable morphological blasts in bone marrow).
      2. Consolidation (Intensification) Phase: Administered post-remission to eradicate residual submicroscopic disease.
      3. Maintenance Phase: Prolonged, low-dose chemotherapy to prevent disease recurrence.
    • Remission Definition: Absence of detectable morphological leukemia; microscopic malignant cells may persist.
    • Methotrexate: An antifolate chemotherapeutic agent that inhibits dihydrofolate reductase, blocking folic acid metabolism required for purine and DNA synthesis; administered orally, intravenously, intramuscularly, or intrathecally.
    • Myelosuppression: Profound bone marrow suppression is a common side effect of systemic chemotherapy.
    • Tumor Lysis Syndrome (TLS): An oncologic emergency caused by massive, rapid chemotherapy-induced destruction of malignant cells; manifests with hyperkalemia, hyperphosphatemia, and hyperuricemia.
    • Allopurinol: Administered during induction chemotherapy to prevent hyperuricemia by inhibiting xanthine oxidase, preventing urate crystallization and acute kidney injury.

  • Supportive and Nursing Priorities:

    • Neutropenic Protocols: Infection prevention via strict hand hygiene, isolation, and avoidance of infectious contacts.
    • Transfusion Therapy: Immunocompromised leukemia patients receiving blood products must receive irradiated blood products to prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD).

Septic Arthritis and Progression to Septic Shock

  • Septic Arthritis Etiology and Pathogenesis:

    • Causative Organism: Staphylococcus aureus is the most common pathogen isolated from synovial fluid aspirates.
    • Microbiological Identification: Methicillin-Resistant Staphylococcus aureus (MRSA) appears on Gram stain as Gram-positive (crystal violet positive) cocci.
    • Predisposing Risk Factors: History of intravenous drug use (IVDU), excessive alcohol consumption, recurrent cutaneous infections, and poor hygiene.
    • Anatomical Localization in IVDU: High predilection for fibrocartilaginous axial joints, particularly the sternoclavicular joint.
    • Medical Management: Immediate administration of targeted intravenous antibiotics and surgical drainage.

  • Progression to Septic Shock:

    • Clinical and Diagnostic Criteria for Septic Shock:
      • Serum lactate elevated to ≥4 mmol/L\ge 4\,\text{mmol/L}.
      • Persistent systolic arterial hypotension (SBP<90 mmHg\text{SBP} < 90\,\text{mmHg}).
      • Persistent oliguria with urine output falling below <0.5 mL/kg/hr< 0.5\,\text{mL/kg/hr} despite aggressive intravenous fluid administration.

  • Coagulation Mechanisms and Anticoagulation:

    • Intrinsic Coagulation Pathway: Initiated by blood exposure to negatively charged subendothelial collagen.
    • Virchow's Triad: Three factors driving intravascular thrombus formation: (1) Venous stasis; (2) Vascular endothelial wall injury; (3) Hypercoagulability.
    • Heparin: Binds and activates antithrombin III, enhancing its ability to inactivate thrombin and factor Xa.
    • Warfarin: Monitored clinically using the International Normalized Ratio (INR), which standardizes prothrombin time.